GRI Bio says Phase 2a trial shows GRI-0621 lifts placebo-adjusted FVC in IPF patients at 12 weeks

• Gri Bio disclosed new Phase 2a data on GRI-0621 in idiopathic pulmonary fibrosis, already presented at ERS 2026.
• Results supported a consistent biological effect aligned with reduced fibrosis activity, tissue repair signals, improved symptoms, and stable lung function.
• Patients on GRI-0621 were more likely to show improved lung function versus placebo, supporting continued development despite exploratory endpoints.
• Safety profile appeared manageable over 12 weeks, with fewer key tolerability complaints than placebo in this small study.
• Company plans to advance GRI-0621 into a longer-duration study, targeting a 52-week evaluation alongside standard antifibrotic therapy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gri Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609080815PRIMZONEFULLFEED9822651) on September 08, 2026, and is solely responsible for the information contained therein.